keyword
MENU ▼
Read by QxMD icon Read
search

Hypoactive sexual desire disorder

keyword
https://www.readbyqxmd.com/read/28918588/a-practical-approach-to-managing-hypoactive-sexual-desire-disorder-in-women-with-diabetes
#1
REVIEW
Charmaine Rochester-Eyeguokan, Lisa Meade
Female sexual dysfunction (FSD) is highly prevalent in women with diabetes mellitus (DM), yet it remains unaddressed, undiagnosed, and untreated. Hypoactive sexual desire disorder (HSDD) is the most common complaint among women with FSD, but there is a paucity of research into its multifactorial etiology. Flibanserin is the only therapy approved by the US Food and Drug Administration for treating acquired, generalized HSDD in premenopausal women. Women with DM diagnosed with HSDD may require a multidisciplinary approach for optimal management...
September 16, 2017: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/28885410/distressing-sexual-function-at-midlife-unmet-needs-practical-diagnoses-and-available-treatments
#2
James A Simon, Vanessa A Lukas
Female sexual dysfunction (FSD) is characterized as chronic sexual symptoms that manifest with personal distress in the domains of desire, arousal, orgasm, and pain. Extensive epidemiologic evidence estimates that almost 50% of perimenopausal and postmenopausal women experience FSD. Screening for FSD is not readily conducted and patient-physician discussion of sexuality is limited by the lack of physician training on the topic and by the patient-held belief that sexual issues are not medical in nature. The purpose of this commentary is to provide clinicians with a framework to approach the discussion of FSD, to clinically identify FSD through patient symptoms and physical signs, and to manage FSD in perimenopausal and postmenopausal patients with the available U...
September 5, 2017: Obstetrics and Gynecology
https://www.readbyqxmd.com/read/28865901/neuroimaging-of-female-sexual-desire-and-hypoactive-sexual-desire-disorder
#3
REVIEW
Stephanie Cacioppo
INTRODUCTION: Recent advances in neuroimaging offer an unprecedented window into the female sexual brain. The small samples and poor statistical power of individual functional magnetic resonance imaging studies have limited what can be gleaned about the systematic brain network that is involved in female sexual desire and female sexual dysfunction (eg, hypoactive sexual desire disorder [HSDD]). AIM: To quantitatively determine the brain network involved in HSDD...
August 30, 2017: Sexual Medicine Reviews
https://www.readbyqxmd.com/read/28817365/effect-of-flibanserin-treatment-on-body-weight-in-premenopausal-and-postmenopausal-women-with-hypoactive-sexual-desire-disorder-a-post-hoc-analysis
#4
Susan G Kornstein, James A Simon, Stuart C Apfel, James Yuan, Krista A Barbour, Robert Kissling
BACKGROUND: Flibanserin, a 5-HT1A agonist and 5-HT2A antagonist, is indicated for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. This post hoc analysis evaluated the effect of flibanserin treatment on body weight in premenopausal and postmenopausal women with HSDD. MATERIALS AND METHODS: This analysis included three 24-week, double-blind, placebo-controlled studies of flibanserin 100 mg each bedtime (qhs) in premenopausal women, a similarly designed study in postmenopausal women, and a 52-week, open-label extension study in premenopausal women...
August 17, 2017: Journal of Women's Health
https://www.readbyqxmd.com/read/28814122/flibanserin-toxicity-in-a-toddler-following-ingestion
#5
Nicholas Granzella, Betty C Chen, Geoffrey S Baird, Matthew Valento
INTRODUCTION: Flibanserin is a medication recently approved by the FDA for treatment of generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. Its mechanism of action is not fully understood but is thought to modulate serotonin receptors and increase levels of norepinephrine and dopamine. While much is known about toxicity of other drugs which affect these systems, there is little information about toxicity of flibanserin at this time. CASE: We present a case of a 2-year-old boy who ingested an estimated 600 mg of his mother's flibanserin...
August 17, 2017: Clinical Toxicology
https://www.readbyqxmd.com/read/28757356/flibanserin-from-bench-to-bedside
#6
REVIEW
Erin M Dooley, Melanie K Miller, Anita H Clayton
INTRODUCTION: The process of approval for flibanserin (trade name Addyi) has been associated with controversy since before its approval on August 18, 2015. This argument centered on challenges to the validity of the diagnosis of hypoactive sexual desire disorder in women and the safety and efficacy of the drug. AIM: To explore the process of Food and Drug Administration (FDA) approval for flibanserin and delve further into the research, concerns, and various roadblocks to its approval...
July 27, 2017: Sexual Medicine Reviews
https://www.readbyqxmd.com/read/28666836/flibanserin-efficacy-and-safety-in-premenopausal-women-with-generalized-acquired-hypoactive-sexual-desire-disorder
#7
REVIEW
William A Fisher, Robert E Pyke
INTRODUCTION: Flibanserin is a postsynaptic 5-HT-1A agonist and 5-HT-2A antagonist for the treatment of generalized acquired hypoactive sexual desire disorder in premenopausal women. AIM: To review and evaluate the efficacy and safety of flibanserin. METHODS: We review and critique the appropriateness of the co-primary and secondary end points used in the flibanserin pivotal trial research program. We review the efficacy and safety parameters of this drug based on the published literature and related sources...
June 27, 2017: Sexual Medicine Reviews
https://www.readbyqxmd.com/read/28609390/androgens-in-postmenopausal-women-a-review
#8
Jan L Shifren, Susan R Davis
There is significant interest in the use of androgen therapy for postmenopausal women. This review provides background on endogenous androgens in women, describes factors that affect circulating androgen concentrations, and examines the relationship between low levels of androgens and sexual problems. Possible effects of androgens in postmenopausal women beyond sexual function also are discussed. Clinical trials of androgen therapy for the treatment of hypoactive sexual desire disorder are reviewed, with a discussion of potential risks...
August 2017: Menopause: the Journal of the North American Menopause Society
https://www.readbyqxmd.com/read/28608926/the-pharmacodynamic-effects-of-combined-administration-of-flibanserin-and-alcohol
#9
D M Stevens, J M Weems, L Brown, K A Barbour, S M Stahl
WHAT IS KNOWN AND OBJECTIVE: Flibanserin is a serotonin 5-HT1A agonist and 5-HT2A antagonist approved for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. Because of the increased risk of hypotension- and syncope-related adverse events (AEs) observed with coadministration of flibanserin and alcohol, alcohol use is contraindicated. To provide a more comprehensive understanding of the interaction between flibanserin and alcohol, the results of a dedicated phase 1 alcohol-interaction study and a pooled analysis of phase 3 studies of premenopausal women with HSDD are presented...
June 13, 2017: Journal of Clinical Pharmacy and Therapeutics
https://www.readbyqxmd.com/read/28583342/flibanserin-in-postmenopausal-women-with-hypoactive-sexual-desire-disorder-results-of-the-plumeria-study
#10
David J Portman, Louise Brown, James Yuan, Robert Kissling, Sheryl A Kingsberg
BACKGROUND: Hypoactive sexual desire disorder (HSDD) is a common sexual disorder in younger and older women. Flibanserin is approved for the treatment of acquired generalized HSDD in premenopausal women only. The efficacy of flibanserin for postmenopausal women with HSDD was demonstrated in the first of two North American randomized, double-blinded, placebo-controlled trials (SNOWDROP). AIM: To evaluate the safety and efficacy of flibanserin in postmenopausal women with HSDD in a second randomized, double-blinded, placebo-controlled trial (PLUMERIA)...
June 2017: Journal of Sexual Medicine
https://www.readbyqxmd.com/read/28442935/new-developments-in-the-treatment-of-hypoactive-sexual-desire-disorder-a-focus-on-flibanserin
#11
REVIEW
Christopher J Jayne, Michael J Heard, Sarah Zubair, Dustie L Johnson
The objective of the authors is to highlight the historical complexities for the diagnosis and treatment of hypoactive sexual desire disorder (HSDD) with a focus on Flibanserin. A systematic review of the medical literature published in PubMed using the search terms HSDD and Flibanserin was conducted. Each author reviewed the results of the systematic review for articles to include in this study. HSDD is defined as a persistent or recurrent deficiency or absence of sexual fantasies and desire for sexual activity causing marked distress or interpersonal difficulty that is not better accounted for by another diagnosis...
2017: International Journal of Women's Health
https://www.readbyqxmd.com/read/28434386/flibanserin-the-female-viagra
#12
Desiree Shapiro, Deanna Stevens, Stephen M Stahl
This article provides a clinically relevant review of the first medication approved by the US Food and Drug Administration for hypoactive sexual desire disorder (HSDD) in premenopausal women. In this short piece, the human sexual response cycle and its relevance to HSDD will be described as well as the pharmacological mechanism of action of flibanserin. Finally, efficacy and safety data of this new medication will be summarised.
April 24, 2017: International Journal of Psychiatry in Clinical Practice
https://www.readbyqxmd.com/read/28403601/urinary-symptoms-and-sexual-dysfunction-among-italian-men-the-results-of-the-controllati-survey
#13
Vincenzo Mirone, Roberto Carone, Giuseppe Carrieri, Elisabetta Costantini, Giuseppe Morgia, Giuseppe Mario Ludovico, Donata Villari, Fabio Parazzini
OBJECTIVE: Prevention may improve the quality of life and sexual and reproductive health. To improve prevention require a comprehensive research approach that examines the frequency and risk factors for urologic conditions. In June 2016 the Italian Urologic Society coordinated a preventive initiative : the 1st Week of Male Urologic Prevention "#Controllati". MATERIAL AND METHODS: During the 1st Week of Male Urologic Prevention "#Controllati", men aged 18 years or more were invited to attend participating urologic centers for a free of charge visit for counseling about urologic or andrologic conditions...
March 31, 2017: Archivio Italiano di Urologia, Andrologia
https://www.readbyqxmd.com/read/28401285/individual-prolactin-reactivity-modulates-response-of-nucleus-accumbens-to-erotic-stimuli-during-acute-cannabis-intoxication-an-fmri-pilot-study
#14
R Androvicova, J Horacek, J Tintera, J Hlinka, J Rydlo, D Jezova, M Balikova, T Hlozek, P Miksatkova, M Kuchar, M Roman, P Tomicek, F Tyls, M Viktorinova, T Palenicek
RATIONALE: Self-report studies indicate that cannabis could increase sexual desire in some users. We hypothesized that intoxication increases activation of brain areas responsive to visual erotica, which could be useful in the treatment of hypoactive sexual desire disorder, a condition marked by a lack of sexual desire. OBJECTIVES: The aim of this study is to assess the aphrodisiacal properties of cannabis. METHODS: We conducted an open-randomized study with 21 heterosexual casual cannabis users...
April 12, 2017: Psychopharmacology
https://www.readbyqxmd.com/read/28397671/-flibanserin-as-pharmacological-therapy-of-inhibited-sexual-desire-in-women
#15
Anne Sofie Eldon, Annamaria Giraldi
Flibanserin was approved by the Food and Drug Administration in the USA in August 2015 as the first drug for the treatment of American women with the dysfunction hypoactive sexual desire disorder (HSDD) and is a 5-HT1A agonist and 5-HT2A antagonist. The neurophysiological effects of flibanserin on these receptors are consistent with the clinical effects, i.e. significantly increasing sexual desire and frequency of satisfying sexual experiences. As such, shifting the balance between inhibitory and excitatory neurotransmitters of importance to sexual desire, flibanserin pharmacologically broaches a possible new approach to the treatment of HSDD...
February 13, 2017: Ugeskrift for Laeger
https://www.readbyqxmd.com/read/28372939/c-tactile-mediated-erotic-touch-perception-relates-to-sexual-desire-and-performance-in-a-gender-specific-way
#16
Johanna Bendas, Janniko R Georgiadis, Gerhard Ritschel, Håkan Olausson, Kerstin Weidner, Ilona Croy
BACKGROUND: Unmyelinated low-threshold mechanoreceptors-the so-called C-tactile (CT) afferents-play a crucial role in the perception and conduction of caressing and pleasant touch sensations and significantly contribute to the concept of erotic touch perception. AIM: To investigate the relations between sexual desire and sexual performance and the perception of touch mediated by CT afferents. METHODS: Seventy healthy participants (28 men, 42 women; mean age ± SD = 24...
May 2017: Journal of Sexual Medicine
https://www.readbyqxmd.com/read/28364864/evaluation-of-the-efficacy-and-safety-of-tribulus-terrestris-in-male-sexual-dysfunction-a-prospective-randomized-double-blind-placebo-controlled-clinical-trial
#17
RANDOMIZED CONTROLLED TRIAL
Zdravko Kamenov, Svetlana Fileva, Krassimir Kalinov, Emmanuele A Jannini
OBJECTIVE: The primary objectives were to compare the efficacy of extracts of the plant Tribulus terrestris (TT; marketed as Tribestan), in comparison with placebo, for the treatment of men with erectile dysfunction (ED) and with or without hypoactive sexual desire disorder (HSDD), as well as to monitor the safety profile of the drug. The secondary objective was to evaluate the level of lipids in blood during treatment. PARTICIPANTS AND DESIGN: Phase IV, prospective, randomized, double-blind, placebo-controlled clinical trial in parallel groups...
May 2017: Maturitas
https://www.readbyqxmd.com/read/28337949/efficacy-of-metacognitive-therapy-for-hypoactive-sexual-desire-disorder-among-iranian-couples
#18
Mohammad Arash Ramezani, Khodabakhsh Ahmadi, Mohammadali Besharat, Sima Noohi, Afagh Ghaemmaghami
OBJECTIVE: The aim of present study was to compare the efficacy of metacognitive therapy (MCT) against Masters-Johnson sex therapy (MJST) for hypoactive sexual desire disorder (HSDD) in Iranian couples. METHODS: A randomized treatment trial was conducted. Participants were recruited from the family counseling clinics in Tehran and Isfahan. All were suffering from HSDD as defined by DSM-IV-R criteria. They were assigned randomly to two groups that received 10 sessions of either MCT or MJST...
March 24, 2017: Psychotherapy Research: Journal of the Society for Psychotherapy Research
https://www.readbyqxmd.com/read/28291031/a-sex-specific-dose-response-curve-for-testosterone-could-excessive-testosterone-limit-sexual-interaction-in-women
#19
Jill M Krapf, James A Simon
Testosterone treatment increases sexual desire and well-being in women with hypoactive sexual desire disorder; however, many studies have shown only modest benefits limited to moderate doses. Unlike men, available data indicate women show a bell-shaped dose-response curve for testosterone, wherein a threshold dosage of testosterone leads to desirable sexual function effects, but exceeding this threshold results in a lack of further positive sexual effects or may have a negative impact. Emotional and physical side-effects of excess testosterone, including aggression and virilization, may counteract the modest benefits on sexual interaction, providing a possible explanation for a threshold dose of testosterone in women...
April 2017: Menopause: the Journal of the North American Menopause Society
https://www.readbyqxmd.com/read/28278441/facilitation-of-sexual-behavior-in-ovariectomized-rats-by-estradiol-and-testosterone-a-preclinical-model-of-androgen-effects-on-female-sexual-desire
#20
Sherri Lee Jones, Nafissa Ismail, James G Pfaus
In the United States and Canada, there are no approved treatments for hypoactive sexual desire disorder in postmenopausal women. Testosterone improves female sexual desire in naturally- and surgically-menopausal women maintained on estrogen replacement therapy, and long-term safety data from randomized placebo-controlled clinical trials has yielded promising results. However, the mechanisms associated with its efficacy are not known, and could be addressed using preclinical rodent models; yet there is no systematic evaluation of the effects of estradiol and testosterone on female rat sexual behavior...
February 17, 2017: Psychoneuroendocrinology
keyword
keyword
113009
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"